17,261 trials
Recurrent Bladder Urothelial Carcinoma · Recurrent Renal Pelvis Urothelial Carcinoma · Recurrent Ureter Urothelial Carcinoma
Primary: Response Rate — 8; 18 Participants
Pharmacokinetics
Primary: Unbound Ceftolozane Exposure in the Plasma — 322.6 mg*h/L
Dental Caries
Primary: Dental Caries for Primary Molars Sound at Baseline — 2.3; 3.3 units on a scale — p=0.037
Acute Ischemic Stroke · Thrombotic Disease
Primary: Summary of Treatment-Emergent Adverse Event Reported by >10% of Participants Following Ascending Doses of DS-1040b and a Placebo in Participants With Acute Ischemic…
Wrinkles
Primary: Number of Participants With Haematoma — 10; 23; 6; 11 Participants — p=<0.0001
Tobacco Use Disorder · Schizophrenia
Primary: Preferred Brand Smoke Intake (CO) — 3.30; 3.16; 9.07; 10.54 ppm
Pulmonary Arterial Hypertension · Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — 230 meters
Stage III Melanoma · Stage IV Melanoma · Unresectable Melanoma
Primary: Change in Kinase Expression — -20.87259; -19.64376; -16.41738; -12.5401 Sum Log 2 Fold Change Kinase Expression
Chronic Traumatic Encephalopathy
Primary: Flortaucipir Visual Read as CTE Biomarker — 23; 11; 5; 0 Participants — p=0.2959
Psoriasis
Primary: Number of Participants With PASI-75, or a 75% Improvement From Baseline in PASI Score — 1 Participants
Narcolepsy
Primary: Epworth Sleepiness Scale (ESS) — 14.68; 15.34; 15.34 score on a scale
Actinic Keratosis
Primary: PGA Score — 0.53 score on a scale
Lymphoma
Primary: Number of Subjects With Dose-limiting Toxicities — 0 Participants
Advanced Cancers
Primary: Dyspnea Numeric Rating Scale — -2.0; -1.7; -2.3; -2.5 score on a scale
Multiple Sclerosis · Internuclear Ophthalmoplegia · Fatigue
Primary: Pulse Size Ratio (PSR): Abducting/Adducting Eye Ratio for Saccadic Peak Velocity. — 1.914; 1.937; 1.805; 1.898 ratio — p=0.842672